Clinical Trial Update: Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2) [Phase 4]

View source ↗

Summary

This Phase 4 trial update reports EXIT-BT2 evaluating intravenous tenecteplase for acute ischemic stroke within 4.5–6 hours of onset, and the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Tenecteplase (tenecteplase)

Snippet

Sponsor: General Hospital of Shenyang Military Region | Conditions: Stroke, Ischemic | Phase 4 | Status: RECRUITING